GREAT NECK, N.Y.--(BUSINESS WIRE)--Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 7,763,720, with claims related to DNAs encoding the novel molecular aspects of the Company’s NPC-1 antibody.
